Glioma stem cell signaling: therapeutic opportunities and challenges

References

• Singh SK, Clarke ID, Terasaki M et al. Identification of a cancer stem cell in human brain tumors. Cancer Res.63(18), 5821–5828 (2003).
   PubMed Web of Science ®Google Scholar
• Singh SK, Hawkins C, Clarke ID et al. Identification of human brain tumour initiating cells. Nature432(7015), 396–401 (2004).
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA100(7), 3983–3988 (2003).
   PubMed Web of Science ®Google Scholar
• Matsui W, Huff CA, Wang Q et al. Characterization of clonogenic multiple myeloma cells. Blood103(6), 2332–2336 (2004).
   PubMed Web of Science ®Google Scholar
• Collins AT, Maitland NJ. Prostate cancer stem cells. Eur. J. Cancer42(9), 1213–1218 (2006).
   PubMedGoogle Scholar
• O’Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature445(7123), 106–110 (2007).
   PubMed Web of Science ®Google Scholar
• Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature445(7123), 111–115 (2007).
   PubMed Web of Science ®Google Scholar
• Hemmati HD, Nakano I, Lazareff JA et al. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl Acad. Sci. USA100(25), 15178–15183 (2003).
   PubMed Web of Science ®Google Scholar
• Yuan X, Curtin J, Xiong Y et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene23(58), 9392–9400 (2004).
   PubMed Web of Science ®Google Scholar
• Galli R, Binda E, Orfanelli U et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res.64(19), 7011–7021 (2004).
   PubMed Web of Science ®Google Scholar
• Noble M, Dietrich J. Intersections between neurobiology and oncology: tumor origin, treatment and repair of treatment-associated damage. Trends Neurosci.25(2), 103–107 (2002).
   PubMed Web of Science ®Google Scholar
• Noble M, Dietrich J. The complex identity of brain tumors: emerging concerns regarding origin, diversity and plasticity. Trends Neurosci.27(3), 148–154 (2004).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Imitola J, Kesari S. Mechanisms of disease: the role of stem cells in the biology and treatment of gliomas. Nat. Clin. Pract. Oncol.5(7), 393–404 (2008).
   PubMedGoogle Scholar
• Bao S, Wu Q, McLendon RE et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature444(7120), 756–760 (2006).
   PubMed Web of Science ®Google Scholar
• Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer5(4), 275–284 (2005).
   PubMed Web of Science ®Google Scholar
• Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol.26(17), 2839–2845 (2008).
   PubMed Web of Science ®Google Scholar
• Rich JN. Cancer stem cells in radiation resistance. Cancer Res.67(19), 8980–8984 (2007).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Norden AD, Wen PY. Emerging antiangiogenic treatments for gliomas – efficacy and safety issues. Curr. Opin. Neurol.21(6), 736–744 (2008).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Bao S, Wu Q, Sathornsumetee S et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res.66(16), 7843–7848 (2006).
   PubMed Web of Science ®Google Scholar
• Ma S, Lee TK, Zheng BJ, Chan KW, Guan XY. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene27(12), 1749–1758 (2008).
   PubMed Web of Science ®Google Scholar
• Palmer TD, Willhoite AR, Gage FH. Vascular niche for adult hippocampal neurogenesis. J. Comp. Neurol.425(4), 479–494 (2000).
   PubMed Web of Science ®Google Scholar
• Wurmser AE, Palmer TD, Gage FH. Neuroscience. Cellular interactions in the stem cell niche. Science304(5675), 1253–1255 (2004).
   PubMed Web of Science ®Google Scholar
• Shen Q, Goderie SK, Jin L et al. Endothelial cells stimulate self-renewal and expand neurogenesis of neural stem cells. Science304(5675), 1338–1340 (2004).
   PubMed Web of Science ®Google Scholar
• Alvarez-Buylla A, Lim DA. For the long run: maintaining germinal niches in the adult brain. Neuron41(5), 683–686 (2004).
   PubMed Web of Science ®Google Scholar
• Hagg T. Molecular regulation of adult CNS neurogenesis: an integrated view. Trends Neurosci.28(11), 589–595 (2005).
   PubMed Web of Science ®Google Scholar
• Calabrese C, Poppleton H, Kocak M et al. A perivascular niche for brain tumor stem cells. Cancer Cell11(1), 69–82 (2007).
   PubMed Web of Science ®Google Scholar
• Reynolds BA, Tetzlaff W, Weiss S. A multipotent EGF-responsive striatal embryonic progenitor cell produces neurons and astrocytes. J. Neurosci.12(11), 4565–4574 (1992).
   PubMed Web of Science ®Google Scholar
• Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science255(5052), 1707–1710 (1992).
   PubMed Web of Science ®Google Scholar
• Vescovi AL, Reynolds BA, Fraser DD, Weiss S. bFGF regulates the proliferative fate of unipotent (neuronal) and bipotent (neuronal/astroglial) EGF-generated CNS progenitor cells. Neuron11(5), 951–966 (1993).
   PubMed Web of Science ®Google Scholar
• Gritti A, Parati EA, Cova L et al. Multipotential stem cells from the adult mouse brain proliferate and self-renew in response to basic fibroblast growth factor. J. Neurosci.16(3), 1091–1100 (1996).
   PubMed Web of Science ®Google Scholar
• Kuhn HG, Winkler J, Kempermann G, Thal LJ, Gage FH. Epidermal growth factor and fibroblast growth factor-2 have different effects on neural progenitors in the adult rat brain. J. Neurosci.17(15), 5820–5829 (1997).
   PubMed Web of Science ®Google Scholar
• Palmer TD, Markakis EA, Willhoite AR, Safar F, Gage FH. Fibroblast growth factor-2 activates a latent neurogenic program in neural stem cells from diverse regions of the adult CNS. J. Neurosci.19(19), 8487–8497 (1999).
   PubMed Web of Science ®Google Scholar
• Tropepe V, Sibilia M, Ciruna BG, Rossant J, Wagner EF, van der Kooy D. Distinct neural stem cells proliferate in response to EGF and FGF in the developing mouse telencephalon. Dev. Biol.208(1), 166–188 (1999).
   PubMed Web of Science ®Google Scholar
• Lillien L, Raphael H. BMP and FGF regulate the development of EGF-responsive neural progenitor cells. Development127(22), 4993–5005 (2000).
   PubMed Web of Science ®Google Scholar
• Doetsch F, Petreanu L, Caille I, Garcia-Verdugo JM, Alvarez-Buylla A. EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells. Neuron36(6), 1021–1034 (2002).
   PubMed Web of Science ®Google Scholar
• Jackson EL, Garcia-Verdugo JM, Gil-Perotin S et al. PDGFR α-positive B cells are neural stem cells in the adult SVZ that form glioma-like growths in response to increased PDGF signaling. Neuron51(2), 187–199 (2006).
   PubMed Web of Science ®Google Scholar
• Shi Y, Sun G, Zhao C, Stewart R. Neural stem cell self-renewal. Crit. Rev. Oncol. Hematol.65(1), 43–53 (2008).
   PubMed Web of Science ®Google Scholar
• Schmidt NO, Koeder D, Messing M et al. Vascular endothelial growth factor-stimulated cerebral microvascular endothelial cells mediate the recruitment of neural stem cells to the neurovascular niche. Brain Res.1268, 24–37 (2009).
   PubMed Web of Science ®Google Scholar
• Joy A, Moffett J, Neary K et al. Nuclear accumulation of FGF-2 is associated with proliferation of human astrocytes and glioma cells. Oncogene14(2), 171–183 (1997).
   PubMed Web of Science ®Google Scholar
• Auguste P, Gursel DB, Lemiere S et al. Inhibition of fibroblast growth factor/fibroblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. Cancer Res.61(4), 1717–1726 (2001).
   PubMed Web of Science ®Google Scholar
• Chi AS, Sorensen AG, Jain RK, Batchelor TT. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist14(6), 621–636 (2009).
   PubMedGoogle Scholar
• Martinho O, Longatto-Filho A, Lambros MB et al. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas. Br. J. Cancer101(6), 973–982 (2009).
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature455(7216), 1061–1068 (2008).
   PubMed Web of Science ®Google Scholar
• Kesari S, Stiles CD. The bad seed: PDGF receptors link adult neural progenitors to glioma stem cells. Neuron51(2), 151–153 (2006).
   PubMedGoogle Scholar
• Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res.62(13), 3729–3735 (2002).
   PubMed Web of Science ®Google Scholar
• van der Valk P, Lindeman J, Kamphorst W. Growth factor profiles of human gliomas. Do non-tumour cells contribute to tumour growth in glioma? Ann. Oncol.8(10), 1023–1029 (1997).
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science304(5670), 554 (2004).
   PubMed Web of Science ®Google Scholar
• Castellino RC, Durden DL. Mechanisms of disease: the PI3K–Akt–PTEN signaling node – an intercept point for the control of angiogenesis in brain tumors. Nat. Clin. Pract. Neurol.3(12), 682–693 (2007).
   PubMedGoogle Scholar
• Duerr EM, Rollbrocker B, Hayashi Y et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene16(17), 2259–2264 (1998).
   PubMed Web of Science ®Google Scholar
• Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol.22(14), 2954–2963 (2004).
   PubMed Web of Science ®Google Scholar
• Furnari FB, Fenton T, Bachoo RM et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev.21(21), 2683–2710 (2007).
   PubMed Web of Science ®Google Scholar
• Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res.51(8), 2164–2172 (1991).
   PubMed Web of Science ®Google Scholar
• Wong AJ, Ruppert JM, Bigner SH et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl Acad. Sci. USA89(7), 2965–2969 (1992).
   PubMed Web of Science ®Google Scholar
• Collins VP. Amplified genes in human gliomas. Semin. Cancer Biol.4(1), 27–32 (1993).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353(19), 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Aldape KD, Ballman K, Furth A et al. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J. Neuropathol. Exp. Neurol.63(7), 700–707 (2004).
   PubMed Web of Science ®Google Scholar
• Pelloski CE, Ballman KV, Furth AF et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J. Clin. Oncol.25(16), 2288–2294 (2007).
   PubMed Web of Science ®Google Scholar
• Huang PH, Mukasa A, Bonavia R et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl Acad. Sci. USA104(31), 12867–12872 (2007).
   PubMed Web of Science ®Google Scholar
• Li L, Dutra A, Pak E et al. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro. Oncol.11(1), 9–21 (2009).
   PubMed Web of Science ®Google Scholar
• Bachoo RM, Maher EA, Ligon KL et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell1(3), 269–277 (2002).
   PubMed Web of Science ®Google Scholar
• Lee J, Kotliarova S, Kotliarov Y et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell9(5), 391–403 (2006).
   PubMed Web of Science ®Google Scholar
• Soeda A, Inagaki A, Oka N et al. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J. Biol. Chem.283(16), 10958–10966 (2008).
   PubMedGoogle Scholar
• Shir A, Ogris M, Wagner E, Levitzki A. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice. PLoS Med.3(1), e6 (2006).
   PubMed Web of Science ®Google Scholar
• Zhu H, Acquaviva J, Ramachandran P et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc. Natl Acad. Sci. USA106(8), 2712–2716 (2009).
   PubMed Web of Science ®Google Scholar
• Rich JN, Reardon DA, Peery T et al. Phase II trial of gefitinib in recurrent glioblastoma. J. Clin. Oncol.22(1), 133–142 (2004).
   PubMed Web of Science ®Google Scholar
• Prados MD, Lamborn KR, Chang S et al. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro. Oncol.8(1), 67–78 (2006).
   PubMed Web of Science ®Google Scholar
• Prados MD, Chang SM, Butowski N et al. Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J. Clin. Oncol.27(4), 579–584 (2009).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes AA, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J. Clin. Oncol.27(8), 1268–1274 (2009).
   PubMed Web of Science ®Google Scholar
• Lassman AB, Rossi MR, Raizer JJ et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01–03 and 00–01. Clin. Cancer Res.11(21), 7841–7850 (2005).
   PubMed Web of Science ®Google Scholar
• Spector NL, Xia W, Burris H 3rd et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol.23(11), 2502–2512 (2005).
   PubMed Web of Science ®Google Scholar
• Giannopoulou E, Dimitropoulos K, Argyriou AA, Koutras AK, Dimitrakopoulos F, Kalofonos HP. An in vitro study, evaluating the effect of sunitinib and/or lapatinib on two glioma cell lines. Invest. New Drugs (2009) (Epub ahead of print).
   PubMedGoogle Scholar
• Traxler P, Allegrini PR, Brandt R et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res.64(14), 4931–4941 (2004).
   PubMed Web of Science ®Google Scholar
• Goudar RK, Shi Q, Hjelmeland MD et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol. Cancer Ther.4(1), 101–112 (2005).
   PubMed Web of Science ®Google Scholar
• Rich JN, Sathornsumetee S, Keir ST et al. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin. Cancer Res.11(22), 8145–8157 (2005).
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Johansson M, Bergstrom P, Bergenheim AT, Henriksson R. Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. J. Neurooncol.88(1), 1–9 (2008).
   PubMedGoogle Scholar
• Yeh HJ, Silos-Santiago I, Wang YX, George RJ, Snider WD, Deuel TF. Developmental expression of the platelet-derived growth factor α-receptor gene in mammalian central nervous system. Proc. Natl Acad. Sci. USA90(5), 1952–1956 (1993).
   PubMedGoogle Scholar
• Oumesmar BN, Vignais L, Baron-Van Evercooren A. Developmental expression of platelet-derived growth factor α-receptor in neurons and glial cells of the mouse CNS. J. Neurosci.17(1), 125–139 (1997).
   PubMedGoogle Scholar
• Noble M, Murray K, Stroobant P, Waterfield MD, Riddle P. Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell. Nature333(6173), 560–562 (1988).
   PubMed Web of Science ®Google Scholar
• Hermanson M, Funa K, Hartman M et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res.52(11), 3213–3219 (1992).
   PubMed Web of Science ®Google Scholar
• Westermark B, Heldin CH, Nister M. Platelet-derived growth factor in human glioma. Glia15(3), 257–263 (1995).
   PubMed Web of Science ®Google Scholar
• Rao RD, James CD. Altered molecular pathways in gliomas: an overview of clinically relevant issues. Semin. Oncol.31(5), 595–604 (2004).
   PubMed Web of Science ®Google Scholar
• Fomchenko EI, Holland EC. Platelet-derived growth factor-mediated gliomagenesis and brain tumor recruitment. Neurosurg. Clin. N. Am.18(1), 39–58, viii (2007).
   PubMedGoogle Scholar
• Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev.15(15), 1913–1925 (2001).
   PubMed Web of Science ®Google Scholar
• Holdhoff M, Kreuzer KA, Appelt C et al. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor. Blood Cells Mol. Dis.34(2), 181–185 (2005).
   PubMedGoogle Scholar
• Wen PY, Yung WK, Lamborn KR et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium study 99–08. Clin. Cancer Res.12(16), 4899–4907 (2006).
   PubMed Web of Science ®Google Scholar
• Raymond E, Brandes AA, Dittrich C et al. Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study. J. Clin. Oncol.26(28), 4659–4665 (2008).
   PubMed Web of Science ®Google Scholar
• Roberts WG, Whalen PM, Soderstrom E et al. Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res.65(3), 957–966 (2005).
   PubMed Web of Science ®Google Scholar
• Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature359(6398), 845–848 (1992).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat. Med.9(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature367(6463), 576–579 (1994).
   PubMed Web of Science ®Google Scholar
• Schmidt NO, Westphal M, Hagel C et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int. J. Cancer84(1), 10–18 (1999).
   PubMed Web of Science ®Google Scholar
• Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer77(2), 362–372 (1996).
   PubMed Web of Science ®Google Scholar
• Sanai N, Tramontin AD, Quinones-Hinojosa A et al. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature427(6976), 740–744 (2004).
   PubMed Web of Science ®Google Scholar
• Quinones-Hinojosa A, Sanai N, Soriano-Navarro M et al. Cellular composition and cytoarchitecture of the adult human subventricular zone: a niche of neural stem cells. J. Comp. Neurol.494(3), 415–434 (2006).
   PubMed Web of Science ®Google Scholar
• Gilbertson RJ, Rich JN. Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat. Rev. Cancer7(10), 733–736 (2007).
   PubMed Web of Science ®Google Scholar
• Folkins C, Man S, Xu P, Shaked Y, Hicklin DJ, Kerbel RS. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res.67(8), 3560–3564 (2007).
   PubMed Web of Science ®Google Scholar
• Huang J, Soffer SZ, Kim ES et al. Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol. Cancer Res.2(1), 36–42 (2004).
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Sorensen AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11(1), 83–95 (2007).
   PubMed Web of Science ®Google Scholar
• Stefanik DF, Rizkalla LR, Soi A, Goldblatt SA, Rizkalla WM. Acidic and basic fibroblast growth factors are present in glioblastoma multiforme. Cancer Res.51(20), 5760–5765 (1991).
   PubMed Web of Science ®Google Scholar
• Plate KH, Breier G, Farrell CL, Risau W. Platelet-derived growth factor receptor-β is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab. Invest.67(4), 529–534 (1992).
   PubMed Web of Science ®Google Scholar
• Guo P, Hu B, Gu W et al. Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am. J. Pathol.162(4), 1083–1093 (2003).
   PubMed Web of Science ®Google Scholar
• Dunn IF, Heese O, Black PM. Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J. Neurooncol.50(1–2), 121–137 (2000).
   PubMed Web of Science ®Google Scholar
• Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1a in brain tumors: association with angiogenesis, invasion, and progression. Cancer88(11), 2606–2618 (2000).
   PubMed Web of Science ®Google Scholar
• Du R, Lu KV, Petritsch C et al. HIF1a induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell13(3), 206–220 (2008).
   PubMed Web of Science ®Google Scholar
• Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro. Oncol.7(2), 122–133 (2005).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell86(3), 353–364 (1996).
   PubMed Web of Science ®Google Scholar
• Tuettenberg J, Friedel C, Vajkoczy P. Angiogenesis in malignant glioma – a target for antitumor therapy? Crit. Rev. Oncol. Hematol.59(3), 181–193 (2006).
   PubMed Web of Science ®Google Scholar
• Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science284(5422), 1994–1998 (1999).
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Kim J, Ozawa T et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia2(4), 306–314 (2000).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Han R, Yang Y, Mayer-Proschel M, Noble M. CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J. Biol.5(7), 22 (2006).
   PubMedGoogle Scholar
• Han R, Yang YM, Dietrich J, Luebke A, Mayer-Proschel M, Noble M. Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system. J. Biol.7(4), 12 (2008).
   PubMedGoogle Scholar
• Eyler CE, Foo WC, LaFiura KM, McLendon RE, Hjelmeland AB, Rich JN. Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells26(12), 3027–3036 (2008).
   PubMed Web of Science ®Google Scholar
• Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J. Clin. Oncol.23(23), 5294–5304 (2005).
   PubMed Web of Science ®Google Scholar
• Chang SM, Wen P, Cloughesy T et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs23(4), 357–361 (2005).
   PubMed Web of Science ®Google Scholar
• Kuhn JG, Chang SM, Wen PY et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin. Cancer Res.13(24), 7401–7406 (2007).
   PubMed Web of Science ®Google Scholar
• Varnum-Finney B, Xu L, Brashem-Stein C et al. Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat. Med.6(11), 1278–1281 (2000).
   PubMed Web of Science ®Google Scholar
• Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat. Rev. Cancer3(10), 756–767 (2003).
   PubMed Web of Science ®Google Scholar
• D’Souza B, Miyamoto A, Weinmaster G. The many facets of Notch ligands. Oncogene27(38), 5148–5167 (2008).
   PubMed Web of Science ®Google Scholar
• Pierfelice TJ, Schreck KC, Eberhart CG, Gaiano N. Notch, neural stem cells, and brain tumors. Cold Spring Harb. Symp. Quant Biol.73, 367–375 (2008).
   PubMedGoogle Scholar
• Jarriault S, Brou C, Logeat F, Schroeter EH, Kopan R, Israel A. Signalling downstream of activated mammalian Notch. Nature377(6547), 355–358 (1995).
   PubMed Web of Science ®Google Scholar
• Ohtsuka T, Ishibashi M, Gradwohl G, Nakanishi S, Guillemot F, Kageyama R. Hes1 and Hes5 as notch effectors in mammalian neuronal differentiation. EMBO J.18(8), 2196–2207 (1999).
   PubMedGoogle Scholar
• Solecki DJ, Liu XL, Tomoda T, Fang Y, Hatten ME. Activated Notch2 signaling inhibits differentiation of cerebellar granule neuron precursors by maintaining proliferation. Neuron31(4), 557–568 (2001).
   PubMed Web of Science ®Google Scholar
• Stump G, Durrer A, Klein AL, Lutolf S, Suter U, Taylor V. Notch1 and its ligands δ-like and Jagged are expressed and active in distinct cell populations in the postnatal mouse brain. Mech. Dev.114(1–2), 153–159 (2002).
   PubMedGoogle Scholar
• Gaiano N, Fishell G. The role of notch in promoting glial and neural stem cell fates. Annu. Rev. Neurosci.25, 471–490 (2002).
   PubMed Web of Science ®Google Scholar
• Hitoshi S, Seaberg RM, Koscik C et al. Primitive neural stem cells from the mammalian epiblast differentiate to definitive neural stem cells under the control of Notch signaling. Genes Dev.18(15), 1806–1811 (2004).
   PubMed Web of Science ®Google Scholar
• Yoon K, Gaiano N. Notch signaling in the mammalian central nervous system: insights from mouse mutants. Nat. Neurosci.8(6), 709–715 (2005).
   PubMed Web of Science ®Google Scholar
• Androutsellis-Theotokis A, Leker RR, Soldner F et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature442(7104), 823–826 (2006).
   PubMed Web of Science ®Google Scholar
• Gaiano N, Nye JS, Fishell G. Radial glial identity is promoted by Notch1 signaling in the murine forebrain. Neuron26(2), 395–404 (2000).
   PubMed Web of Science ®Google Scholar
• Tanigaki K, Nogaki F, Takahashi J, Tashiro K, Kurooka H, Honjo T. Notch1 and Notch3 instructively restrict bFGF-responsive multipotent neural progenitor cells to an astroglial fate. Neuron29(1), 45–55 (2001).
   PubMed Web of Science ®Google Scholar
• Swiatek PJ, Lindsell CE, del Amo FF, Weinmaster G, Gridley T. Notch1 is essential for postimplantation development in mice. Genes Dev.8(6), 707–719 (1994).
   PubMed Web of Science ®Google Scholar
• Xue Y, Gao X, Lindsell CE et al. Embryonic lethality and vascular defects in mice lacking the Notch ligand Jagged1. Hum. Mol. Genet.8(5), 723–730 (1999).
   PubMed Web of Science ®Google Scholar
• Krebs LT, Xue Y, Norton CR et al. Notch signaling is essential for vascular morphogenesis in mice. Genes Dev.14(11), 1343–1352 (2000).
   PubMed Web of Science ®Google Scholar
• Hallahan AR, Pritchard JI, Hansen S et al. The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res.64(21), 7794–7800 (2004).
   PubMed Web of Science ®Google Scholar
• Fan X, Mikolaenko I, Elhassan I et al. Notch1 and Notch2 have opposite effects on embryonal brain tumor growth. Cancer Res.64(21), 7787–7793 (2004).
   PubMed Web of Science ®Google Scholar
• Fan X, Matsui W, Khaki L et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res.66(15), 7445–7452 (2006).
   PubMed Web of Science ®Google Scholar
• Purow BW, Haque RM, Noel MW et al. Expression of Notch-1 and its ligands, δ-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res.65(6), 2353–2363 (2005).
   PubMed Web of Science ®Google Scholar
• Shih AH, Holland EC. Notch signaling enhances nestin expression in gliomas. Neoplasia8(12), 1072–1082 (2006).
   PubMed Web of Science ®Google Scholar
• Kanamori M, Kawaguchi T, Nigro JM et al. Contribution of Notch signaling activation to human glioblastoma multiforme. J. Neurosurg.106(3), 417–427 (2007).
   PubMed Web of Science ®Google Scholar
• Zhang XP, Zheng G, Zou L et al. Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol. Cell Biochem.307(1–2), 101–108 (2008).
   PubMed Web of Science ®Google Scholar
• Garber K. Notch emerges as new cancer drug target. J. Natl Cancer Inst.99(17), 1284–1285 (2007).
   PubMed Web of Science ®Google Scholar
• Wang L, Rahn JJ, Lun X et al. γ-secretase represents a therapeutic target for the treatment of invasive glioma mediated by the p75 neurotrophin receptor. PLoS Biol.6(11), e289 (2008).
   Web of Science ®Google Scholar
• LoRusso PM, Demuth T, Heath E et al. Phase I study of MK-0752, a Notch inhibitor, in patients with breast cancer and other solid tumors. In: Proceedings of the American Association for Cancer Research (AACR). Denver, CO, USA (2009) (Abstract 3605).
   Google Scholar
• Machold R, Hayashi S, Rutlin M et al. Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron39(6), 937–950 (2003).
   PubMed Web of Science ®Google Scholar
• Park Y, Rangel C, Reynolds MM et al.Drosophila perlecan modulates FGF and hedgehog signals to activate neural stem cell division. Dev. Biol.253(2), 247–257 (2003).
   PubMedGoogle Scholar
• Lai K, Kaspar BK, Gage FH, Schaffer DV. Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat. Neurosci.6(1), 21–27 (2003).
   PubMed Web of Science ®Google Scholar
• Palma V, Lim DA, Dahmane N et al. Sonic hedgehog controls stem cell behavior in the postnatal and adult brain. Development132(2), 335–344 (2005).
   PubMed Web of Science ®Google Scholar
• Cai C, Thorne J, Grabel L. Hedgehog serves as a mitogen and survival factor during embryonic stem cell neurogenesis. Stem Cells26(5), 1097–1108 (2008).
   PubMed Web of Science ®Google Scholar
• Han YG, Spassky N, Romaguera-Ros M et al. Hedgehog signaling and primary cilia are required for the formation of adult neural stem cells. Nat. Neurosci.11(3), 277–284 (2008).
   PubMed Web of Science ®Google Scholar
• Komada M, Saitsu H, Kinboshi M, Miura T, Shiota K, Ishibashi M. Hedgehog signaling is involved in development of the neocortex. Development135(16), 2717–2727 (2008).
   PubMedGoogle Scholar
• Goodrich LV, Milenkovic L, Higgins KM, Scott MP. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science277(5329), 1109–1113 (1997).
   PubMed Web of Science ®Google Scholar
• Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature415(6870), 436–442 (2002).
   PubMed Web of Science ®Google Scholar
• Dahmane N, Sanchez P, Gitton Y et al. The sonic hedgehog–Gli pathway regulates dorsal brain growth and tumorigenesis. Development128(24), 5201–5212 (2001).
   PubMed Web of Science ®Google Scholar
• Berman DM, Karhadkar SS, Hallahan AR et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science297(5586), 1559–1561 (2002).
   PubMed Web of Science ®Google Scholar
• Pascadi Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat. Rev. Cancer3(12), 903–911 (2003).
   PubMedGoogle Scholar
• Ruizi Altaba A, Sanchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat. Rev. Cancer2(5), 361–372 (2002).
   PubMedGoogle Scholar
• Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG–GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr. Biol.17(2), 165–172 (2007).
   PubMed Web of Science ®Google Scholar
• Bar EE, Chaudhry A, Lin A et al. Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells25(10), 2524–2533 (2007).
   PubMed Web of Science ®Google Scholar
• Rudin CM, Hann CL, Laterra J et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N. Engl. J. Med.361(12), 1173–1178 (2009).
   PubMed Web of Science ®Google Scholar
• Brivanlou AH, Darnell JE Jr. Signal transduction and the control of gene expression. Science295(5556), 813–818 (2002).
   PubMed Web of Science ®Google Scholar
• Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and β-catenin signalling: diseases and therapies. Nat. Rev. Genet.5(9), 691–701 (2004).
   PubMed Web of Science ®Google Scholar
• Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature434(7035), 843–850 (2005).
   PubMed Web of Science ®Google Scholar
• Ikeya M, Lee SM, Johnson JE, McMahon AP, Takada S. Wnt signalling required for expansion of neural crest and CNS progenitors. Nature389(6654), 966–970 (1997).
   PubMed Web of Science ®Google Scholar
• Chenn A, Walsh CA. Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science297(5580), 365–369 (2002).
   PubMed Web of Science ®Google Scholar
• Zechner D, Fujita Y, Hulsken J et al. β-catenin signals regulate cell growth and the balance between progenitor cell expansion and differentiation in the nervous system. Dev. Biol.258(2), 406–418 (2003).
   PubMed Web of Science ®Google Scholar
• Wexler EM, Paucer A, Kornblum HI, Palmer TD, Geschwind DH. Endogenous Wnt signaling maintains neural progenitor cell potency. Stem Cells27(5), 1130–1141 (2009).
   PubMed Web of Science ®Google Scholar
• Lee HY, Kleber M, Hari L et al. Instructive role of Wnt/β-catenin in sensory fate specification in neural crest stem cells. Science303(5660), 1020–1023 (2004).
   PubMed Web of Science ®Google Scholar
• Lie DC, Colamarino SA, Song HJ et al. Wnt signalling regulates adult hippocampal neurogenesis. Nature437(7063), 1370–1375 (2005).
   PubMed Web of Science ®Google Scholar
• Gulacsi AA, Anderson SA. β-catenin-mediated Wnt signaling regulates neurogenesis in the ventral telencephalon. Nat. Neurosci.11(12), 1383–1391 (2008).
   PubMedGoogle Scholar
• Zurawel RH, Chiappa SA, Allen C, Raffel C. Sporadic medulloblastomas contain oncogenic β-catenin mutations. Cancer Res.58(5), 896–899 (1998).
   PubMed Web of Science ®Google Scholar
• Yokota N, Nishizawa S, Ohta S et al. Role of Wnt pathway in medulloblastoma oncogenesis. Int. J. Cancer101(2), 198–201 (2002).
   PubMed Web of Science ®Google Scholar
• Marino S. Medulloblastoma: developmental mechanisms out of control. Trends Mol. Med.11(1), 17–22 (2005).
   PubMed Web of Science ®Google Scholar
• Roth W, Wild-Bode C, Platten M et al. Secreted frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells. Oncogene19(37), 4210–4220 (2000).
   PubMedGoogle Scholar
• Zhang Z, Schittenhelm J, Guo K et al. Upregulation of frizzled 9 in astrocytomas. Neuropathol. Appl. Neurobiol.32(6), 615–624 (2006).
   PubMed Web of Science ®Google Scholar
• Pu P, Zhang Z, Kang C et al. Downregulation of Wnt2 and β-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther.16(4), 351–361 (2009).
   PubMed Web of Science ®Google Scholar
• Groszer M, Erickson R, Scripture-Adams DD et al. Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science294(5549), 2186–2189 (2001).
   PubMed Web of Science ®Google Scholar
• Li L, Liu F, Salmonsen RA et al. PTEN in neural precursor cells: regulation of migration, apoptosis, and proliferation. Mol. Cell. Neurosci.20(1), 21–29 (2002).
   PubMedGoogle Scholar
• Baker SJ, McKinnon PJ. Tumour-suppressor function in the nervous system. Nat. Rev. Cancer4(3), 184–196 (2004).
   PubMedGoogle Scholar
• Koul D. PTEN signaling pathways in glioblastoma. Cancer Biol. Ther.7(9), 1321–1325 (2008).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res.13(2 Pt 1), 378–381 (2007).
   PubMed Web of Science ®Google Scholar
• Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M. The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature397(6715), 164–168 (1999).
   PubMed Web of Science ®Google Scholar
• Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M. Stem cells and cancer; the polycomb connection. Cell118(4), 409–418 (2004).
   PubMed Web of Science ®Google Scholar
• Molofsky AV, He S, Bydon M, Morrison SJ, Pardal R. Bmi-1 promotes neural stem cell self-renewal and neural development but not mouse growth and survival by repressing the p16Ink4a and p19Arf senescence pathways. Genes Dev.19(12), 1432–1437 (2005).
   PubMed Web of Science ®Google Scholar
• Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature425(6961), 962–967 (2003).
   PubMed Web of Science ®Google Scholar
• Dirks P. Bmi1 and cell of origin determinants of brain tumor phenotype. Cancer Cell12(4), 295–297 (2007).
   PubMedGoogle Scholar
• Lessard J, Sauvageau G. Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature423(6937), 255–260 (2003).
   PubMed Web of Science ®Google Scholar
• Leung C, Lingbeek M, Shakhova O et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature428(6980), 337–341 (2004).
   PubMed Web of Science ®Google Scholar
• Dukers DF, van Galen JC, Giroth C et al. Unique polycomb gene expression pattern in Hodgkin’s lymphoma and Hodgkin’s lymphoma-derived cell lines. Am. J. Pathol.164(3), 873–881 (2004).
   PubMedGoogle Scholar
• Bruggeman SW, Hulsman D, Tanger E et al. Bmi1 controls tumor development in an Ink4a/Arf-independent manner in a mouse model for glioma. Cancer Cell12(4), 328–341 (2007).
   PubMed Web of Science ®Google Scholar
• Godlewski J, Newton HB, Chiocca EA, Lawler SE. MicroRNAs and glioblastoma; the stem cell connection. Cell Death Differ. (2009).
   PubMedGoogle Scholar
• Lawler S, Chiocca EA. Emerging functions of microRNAs in glioblastoma. J. Neurooncol.92(3), 297–306 (2009).
   PubMed Web of Science ®Google Scholar
• Pang JC, Kwok WK, Chen Z, Ng HK. Oncogenic role of microRNAs in brain tumors. Acta Neuropathol.117(6), 599–611 (2009).
   PubMed Web of Science ®Google Scholar
• Silber J, Lim DA, Petritsch C et al. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med.6, 14 (2008).
   PubMed Web of Science ®Google Scholar
• Godlewski J, Nowicki MO, Bronisz A et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res.68(22), 9125–9130 (2008).
   PubMed Web of Science ®Google Scholar
• Desano JT, Xu L. MicroRNA regulation of cancer stem cells and therapeutic implications. AAPS J.11(4), 682–692 (2009).
   PubMed Web of Science ®Google Scholar
• Li Y, Guessous F, Zhang Y et al. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res.69(19), 7569–7576 (2009).
   PubMed Web of Science ®Google Scholar
• Petri A, Lindow M, Kauppinen S. MicroRNA silencing in primates: towards development of novel therapeutics. Cancer Res.69(2), 393–395 (2009).
   PubMed Web of Science ®Google Scholar
• Pillay V, Allaf L, Wilding AL et al. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia11(5), 448–458 (2009).
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X et al. An integrated genomic analysis of human glioblastoma multiforme. Science321(5897), 1807–1812 (2008).
   PubMed Web of Science ®Google Scholar
• Monje ML, Mizumatsu S, Fike JR, Palmer TD. Irradiation induces neural precursor-cell dysfunction. Nat. Med.8(9), 955–962 (2002).
   PubMed Web of Science ®Google Scholar
• Dietrich J, Monje M, Wefel J, Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist13(12), 1285–1295 (2008).
   PubMed Web of Science ®Google Scholar
• Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell15(3), 167–170 (2009).
   PubMed Web of Science ®Google Scholar
• Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell15(3), 232–239 (2009).
   PubMed Web of Science ®Google Scholar
• Paez-Ribes M, Allen E, Hudock J et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell15(3), 220–231 (2009).
   PubMed Web of Science ®Google Scholar